$ANIK
Anika Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000117184322003350 Filed on May 06, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $36.69M $34.29M
YoY Change 7.0% -3.12%
Cost Of Revenue $14.89M $13.32M
YoY Change 11.8% -6.21%
Gross Profit $21.80M $20.97M
YoY Change 3.96% -1.05%
Gross Profit Margin 59.42% 61.16%
Selling, General & Admin $19.20M $18.18M
YoY Change 5.65% 25.94%
% of Gross Profit 88.06% 86.65%
Research & Development $6.157M $6.361M
YoY Change -3.21% 5.14%
% of Gross Profit 28.24% 30.33%
Depreciation & Amortization $3.617M $3.510M
YoY Change 3.05% 27.17%
% of Gross Profit 16.59% 16.74%
Operating Expenses $25.36M $24.54M
YoY Change 3.35% 19.8%
Operating Profit -$3.554M $1.258M
YoY Change -382.51% -82.27%
Interest Expense -$154.0K -$43.00K
YoY Change 258.14% -115.41%
% of Operating Profit -3.42%
Other Income/Expense, Net
YoY Change
Pretax Income -$3.708M $1.215M
YoY Change -405.19% -83.52%
Income Tax -$800.0K -$1.600M
% Of Pretax Income -131.69%
Net Earnings -$2.933M $2.838M
YoY Change -203.35% -51.01%
Net Earnings / Revenue -7.99% 8.28%
Basic Earnings Per Share -$0.20 $0.20
Diluted Earnings Per Share -$0.20 $0.20
COMMON SHARES
Basic Shares Outstanding 14.47M 14.34M
Diluted Shares Outstanding 14.47M 14.44M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.33M $94.60M
YoY Change -4.52% 2.49%
Cash & Equivalents $90.33M $94.60M
Short-Term Investments $0.00
Other Short-Term Assets $10.46M $9.600M
YoY Change 8.95% 68.42%
Inventory $35.23M $42.72M
Prepaid Expenses
Receivables $29.31M $26.51M
Other Receivables $0.00 $0.00
Total Short-Term Assets $165.3M $173.5M
YoY Change -4.7% 7.66%
LONG-TERM ASSETS
Property, Plant & Equipment $47.95M $49.13M
YoY Change -2.4% -9.41%
Goodwill $7.625M $8.045M
YoY Change -5.22% -76.2%
Intangibles $80.44M $88.99M
YoY Change -9.61% -9.86%
Long-Term Investments
YoY Change
Other Assets $20.39M $20.29M
YoY Change 0.46% -26.23%
Total Long-Term Assets $176.9M $188.8M
YoY Change -6.28% -20.61%
TOTAL ASSETS
Total Short-Term Assets $165.3M $173.5M
Total Long-Term Assets $176.9M $188.8M
Total Assets $342.2M $362.3M
YoY Change -5.52% -9.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.444M $8.683M
YoY Change -14.27% -12.35%
Accrued Expenses $15.11M $13.30M
YoY Change 13.62% -17.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $122.0K $100.0K
YoY Change 22.0% -50.0%
Total Short-Term Liabilities $26.99M $46.97M
YoY Change -42.54% 79.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $684.0K $1.583M
YoY Change -56.79% 55.35%
Total Long-Term Liabilities $684.0K $1.583M
YoY Change -56.79% 55.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.99M $46.97M
Total Long-Term Liabilities $684.0K $1.583M
Total Liabilities $27.68M $48.56M
YoY Change -43.0% 78.47%
SHAREHOLDERS EQUITY
Retained Earnings $222.6M $224.3M
YoY Change -0.73% -10.72%
Common Stock $68.94M $57.43M
YoY Change 20.05% 18.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $285.8M $276.7M
YoY Change
Total Liabilities & Shareholders Equity $342.2M $362.3M
YoY Change -5.52% -9.19%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$2.933M $2.838M
YoY Change -203.35% -51.01%
Depreciation, Depletion And Amortization $3.617M $3.510M
YoY Change 3.05% 27.17%
Cash From Operating Activities -$1.869M -$2.431M
YoY Change -23.12% -332.63%
INVESTING ACTIVITIES
Capital Expenditures $1.326M $417.0K
YoY Change 217.99% -42.32%
Acquisitions $0.00 $350.0K
YoY Change -100.0% -99.62%
Other Investing Activities $0.00 $2.150M
YoY Change -100.0% -102.34%
Cash From Investing Activities -$1.326M $1.734M
YoY Change -176.47% -101.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$862.0K -$451.0K
YoY Change 91.13% 219.86%
NET CHANGE
Cash From Operating Activities -$1.869M -$2.431M
Cash From Investing Activities -$1.326M $1.734M
Cash From Financing Activities -$862.0K -$451.0K
Net Change In Cash -$4.061M -$1.218M
YoY Change 233.42% -98.67%
FREE CASH FLOW
Cash From Operating Activities -$1.869M -$2.431M
Capital Expenditures $1.326M $417.0K
Free Cash Flow -$3.195M -$2.848M
YoY Change 12.18% -984.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14543860
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1350000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1442000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1900000 USD
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14441000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14441000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14518000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14518000
CY2021Q4 us-gaap Inventory Net
InventoryNet
36010000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10459000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8289000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
165322000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
168528000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47954000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
684000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1258000 USD
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
9956000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
10157000 USD
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90325000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94386000 USD
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
29313000 USD
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
29843000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
35225000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47602000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20517000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20957000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20385000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20285000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
80436000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
82382000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
7625000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
7781000 USD
CY2022Q1 us-gaap Assets
Assets
342239000 USD
CY2021Q4 us-gaap Assets
Assets
347535000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7444000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7633000 USD
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15233000 USD
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17847000 USD
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4315000 USD
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4315000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
26992000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29795000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18820000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19240000 USD
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
145000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
144000 USD
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
68796000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
67081000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5799000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5718000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
222645000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
225578000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
285787000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
287085000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
342239000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
347535000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36693000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34292000 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14889000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13318000 USD
CY2022Q1 us-gaap Gross Profit
GrossProfit
21804000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
20974000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6157000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6361000 USD
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19201000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18175000 USD
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4820000 USD
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
25358000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
19716000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3554000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1258000 USD
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-154000 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-43000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3708000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1215000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-775000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1623000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2933000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14466000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14343000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14466000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14435000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2933000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-81000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-509000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3014000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2329000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
287085000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
15000 USD
CY2022Q1 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
2545000 USD
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
844000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2933000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-81000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
285787000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
272400000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000 USD
CY2021Q1 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
2259000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
333000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-509000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
276656000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1869000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2933000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1671000 USD
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1545000 USD
CY2022Q1 anik Amortization Of Acquisition Related Intangible Assets
AmortizationOfAcquisitionRelatedIntangibleAssets
1946000 USD
CY2021Q1 anik Amortization Of Acquisition Related Intangible Assets
AmortizationOfAcquisitionRelatedIntangibleAssets
1963000 USD
CY2022Q1 anik Amortization Of Acquisition Related Inventory Step Up
AmortizationOfAcquisitionRelatedInventoryStepUp
0 USD
CY2021Q1 anik Amortization Of Acquisition Related Inventory Step Up
AmortizationOfAcquisitionRelatedInventoryStepUp
2578000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
403000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
405000 USD
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-4820000 USD
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-0 USD
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-831000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2545000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2259000 USD
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-273000 USD
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1162000 USD
CY2022Q1 anik Provision For Doubtful Accounts Net Of Recoveries
ProvisionForDoubtfulAccountsNetOfRecoveries
5000 USD
CY2021Q1 anik Provision For Doubtful Accounts Net Of Recoveries
ProvisionForDoubtfulAccountsNetOfRecoveries
-21000 USD
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
586000 USD
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
277000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-383000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2478000 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
602000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4040000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1189000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-87000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-473000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
188000 USD
CY2022Q1 anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-387000 USD
CY2021Q1 anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-385000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2929000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1254000 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-622000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1242000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2431000 USD
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-0 USD
CY2021Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
350000 USD
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2501000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1326000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
417000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1326000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1734000 USD
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
846000 USD
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
332000 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
31000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
119000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-862000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-451000 USD
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-70000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4061000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1218000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94386000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95817000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90325000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94599000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
728000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
570000 USD
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="vertical-align: top; width: 97%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Nature of Business</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Anika Therapeutics, Inc. (the “Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In early <em style="font: inherit;">2020,</em> the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation solutions provider focused on sports medicine and soft tissue repair, and Arthrosurface, Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company's product portfolio, developed over its <em style="font: inherit;">30</em> years of expertise in hyaluronic acid technology, into joint preservation and restoration space with higher market potential, added new revenue streams, increased and accelerated its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company is subject to risks common to companies in the life sciences industry including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">There continue to be uncertainties regarding the pandemic of the novel coronavirus (“COVID-<em style="font: inherit;">19”</em>), and the Company is closely monitoring the impact of COVID-<em style="font: inherit;">19</em> on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, business partners and broader impact on elective surgeries. The Company is unable to predict the specific impact that COVID-<em style="font: inherit;">19</em> <em style="font: inherit;"> may </em>have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein <em style="font: inherit;"> may </em>change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-<em style="font: inherit;">19.</em></p>
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
26731000 USD
CY2022Q1 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
54757000 USD
CY2021Q4 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
55054000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
35225000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
36010000 USD
CY2022Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
19532000 USD
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
19044000 USD
CY2022Q1 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
54757000 USD
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
16901000 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
16881000 USD
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
13599000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
11442000 USD
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
24257000 USD
CY2021Q4 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
55054000 USD
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6900000 USD
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
9100000 USD
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
112136000 USD
CY2022Q1 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
3218000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
28482000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
80436000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
82382000 USD
CY2022Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P13Y
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1900000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
7781000 USD
CY2022Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-156000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
7625000 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7457000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9523000 USD
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2967000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3590000 USD
CY2022Q1 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2014000 USD
CY2021Q4 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1961000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1145000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1059000 USD
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15233000 USD
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17847000 USD
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 USD
CY2022Q1 anik Revenues From Agreements As Percent Of Total Revenue
RevenuesFromAgreementsAsPercentOfTotalRevenue
0.39 pure
CY2021Q1 anik Revenues From Agreements As Percent Of Total Revenue
RevenuesFromAgreementsAsPercentOfTotalRevenue
0.41 pure
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
300000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1000000.0 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36693000 USD
CY2022Q1 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1 pure
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34292000 USD
CY2021Q1 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
900000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2545000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2259000 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1175993
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
39.56
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
416197
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
28.37
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
437
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.10
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
47858
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
38.23
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1543895
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
36.59
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9000 USD
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
485869
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
41.89
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1543895
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
36.59
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
416197
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y6M
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2022Q1 anik Share Based Compensation Arrangement By Share Based Payment Award Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption
0.1137 pure
CY2021Q1 anik Share Based Compensation Arrangement By Share Based Payment Award Fair Value Per Option
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption
0.1390 pure
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
34.07
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000 USD
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.209 pure
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1600000 USD
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.336 pure
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14466000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14343000
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
92000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14466000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14435000

Files In Submission

Name View Source Status
0001171843-22-003350-index-headers.html Edgar Link pending
0001171843-22-003350-index.html Edgar Link pending
0001171843-22-003350.txt Edgar Link pending
0001171843-22-003350-xbrl.zip Edgar Link pending
anik-20220331.xsd Edgar Link pending
anik-20220331_cal.xml Edgar Link unprocessable
anik-20220331_def.xml Edgar Link unprocessable
anik-20220331_lab.xml Edgar Link unprocessable
anik-20220331_pre.xml Edgar Link unprocessable
anik20220331_10q.htm Edgar Link pending
anik20220331_10q_htm.xml Edgar Link completed
ex_364829.htm Edgar Link pending
ex_364830.htm Edgar Link pending
ex_364831.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending